Mohit Bansal
Stock Analyst at Wells Fargo
(4.03)
# 598
Out of 4,667 analysts
141
Total ratings
59.32%
Success rate
9.5%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Overweight | $100 → $105 | $88.63 | +18.47% | 9 | Nov 7, 2024 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $125 → $110 | $97.44 | +12.89% | 10 | Nov 1, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,200 → $1,050 | $742.09 | +41.49% | 15 | Oct 22, 2024 | |
| TVTX Travere Therapeutics | Upgrades: Overweight | $9 → $27 | $17.86 | +51.18% | 4 | Oct 21, 2024 | |
| HALO Halozyme Therapeutics | Downgrades: Equal-Weight | $58 → $62 | $45.76 | +35.49% | 5 | Oct 7, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $115 → $90 | $62.03 | +45.09% | 5 | Sep 17, 2024 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Overweight | $14 → $12 | $3.52 | +240.91% | 3 | Aug 9, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $875 → $1,000 | $753.41 | +32.73% | 15 | Aug 9, 2024 | |
| AMGN Amgen | Downgrades: Equal-Weight | $320 → $335 | $287.87 | +16.37% | 8 | Aug 7, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $240 → $225 | $156.00 | +44.23% | 11 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $120 | $119.24 | +0.64% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $24.85 | +20.72% | 9 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $205 | $167.76 | +22.20% | 6 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $540 → $555 | $447.27 | +24.09% | 8 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $123.29 | +37.89% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $52 | $58.16 | -10.58% | 7 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $12.60 | +114.29% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $39.34 | +27.10% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $13.55 | +13,737.64% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $18.46 | +62.51% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.11 | +3,143.24% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $20.03 | -5.14% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.66 | +652.22% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $2.71 | +2,114.02% | 4 | Dec 3, 2019 |
Gilead Sciences
Nov 7, 2024
Maintains: Overweight
Price Target: $100 → $105
Current: $88.63
Upside: +18.47%
Merck & Co.
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $97.44
Upside: +12.89%
Regeneron Pharmaceuticals
Oct 22, 2024
Maintains: Overweight
Price Target: $1,200 → $1,050
Current: $742.09
Upside: +41.49%
Travere Therapeutics
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $17.86
Upside: +51.18%
Halozyme Therapeutics
Oct 7, 2024
Downgrades: Equal-Weight
Price Target: $58 → $62
Current: $45.76
Upside: +35.49%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $62.03
Upside: +45.09%
Ironwood Pharmaceuticals
Aug 9, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $3.52
Upside: +240.91%
Eli Lilly
Aug 9, 2024
Maintains: Overweight
Price Target: $875 → $1,000
Current: $753.41
Upside: +32.73%
Amgen
Aug 7, 2024
Downgrades: Equal-Weight
Price Target: $320 → $335
Current: $287.87
Upside: +16.37%
Biogen
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $240 → $225
Current: $156.00
Upside: +44.23%
Aug 1, 2024
Maintains: Equal-Weight
Price Target: $140 → $120
Current: $119.24
Upside: +0.64%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $24.85
Upside: +20.72%
Jul 26, 2024
Maintains: Overweight
Price Target: $200 → $205
Current: $167.76
Upside: +22.20%
Jun 24, 2024
Maintains: Overweight
Price Target: $540 → $555
Current: $447.27
Upside: +24.09%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $123.29
Upside: +37.89%
Apr 18, 2024
Maintains: Equal-Weight
Price Target: $51 → $52
Current: $58.16
Upside: -10.58%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $12.60
Upside: +114.29%
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $39.34
Upside: +27.10%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $13.55
Upside: +13,737.64%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $18.46
Upside: +62.51%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.11
Upside: +3,143.24%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $20.03
Upside: -5.14%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.66
Upside: +652.22%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $2.71
Upside: +2,114.02%